Innovative Research Model Arctoris employs a highly automated, tech-enabled PRO model that emphasizes data quality and rapid drug discovery, which is attractive to pharma and biotech companies seeking scalable and efficient R&D partnerships.

Strategic Collaborations Recent partnerships with prestigious institutions like Cambridge and King's College London, along with collaborations in AI-driven cancer research, position Arctoris as a leader in cutting-edge, AI-powered drug discovery solutions—opportunities to expand client base in academic and biotech sectors.

Acquisition Opportunities The recent acquisition of Eli Lilly's highly automated laboratory suggests an openness to strategic investments or collaborations with organizations aiming to modernize and automate their research facilities.

Growing Financial Footprint With a revenue range of 1 to 10 million USD and recent funding of 8 million USD, Arctoris is positioned for growth and investment, creating opportunities for sales of advanced automation, data analytics, and Lab-as-a-Service solutions.

Market Differentiation As a pioneer in cloud labs and fast-growing biotech automation, Arctoris provides unique selling points—such as AI integration and cloud-based research—that can be leveraged to pitch innovative solutions to pharmaceutical partners seeking next-gen R&D capabilities.